These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38143153)

  • 1. Switching Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide Fumarate (TAF) in Hepatitis B/HIV Co-Infection: A Feasibility Study.
    Lok J; Veloz MFG; Byrne R; Carey I; Childs K; Agarwal K; Nelson M
    Clin Ther; 2024 Feb; 46(2):159-163. PubMed ID: 38143153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients.
    Huang YS; Cheng CY; Sun HY; Cheng SH; Lu PL; Lee CH; Lee YT; Tsai HC; Yang CJ; Liu CE; Liou BH; Lin SP; Huang SH; Ho MW; Tang HJ; Hung CC;
    Microbiol Spectr; 2023 Jun; 11(3):e0512522. PubMed ID: 36988457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.
    Kovari H; Surial B; Tarr PE; Cavassini M; Calmy A; Schmid P; Bernasconi E; Rauch A; Wandeler G; Ledergerber B;
    HIV Med; 2021 Aug; 22(7):623-628. PubMed ID: 33880839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
    DeJesus E; Haas B; Segal-Maurer S; Ramgopal MN; Mills A; Margot N; Liu YP; Makadzange T; McCallister S
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):337-342. PubMed ID: 29368537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study.
    Abe K; Obara T; Kamio S; Kondo A; Imamura J; Goto T; Ito T; Sato H; Takahashi N
    AIDS Res Ther; 2021 Dec; 18(1):94. PubMed ID: 34876151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.
    Li B; Liu Z; Liu X; Liu D; Duan M; Gu Y; Liu Q; Ma Q; Wei Y; Wang Y
    Hepatol Int; 2021 Oct; 15(5):1103-1108. PubMed ID: 34312798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate.
    Kaneko S; Kurosaki M; Tamaki N; Itakura J; Hayashi T; Kirino S; Osawa L; Watakabe K; Okada M; Wang W; Shimizu T; Higuchi M; Takaura K; Yasui Y; Tsuchiya K; Nakanishi H; Takahashi Y; Watanabe M; Izumi N
    J Gastroenterol Hepatol; 2019 Nov; 34(11):2004-2010. PubMed ID: 31017689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial.
    Avihingsanon A; Lu H; Leong CL; Hung CC; Koenig E; Kiertiburanakul S; Lee MP; Supparatpinyo K; Zhang F; Rahman S; D'Antoni ML; Wang H; Hindman JT; Martin H; Baeten JM; Li T;
    Lancet HIV; 2023 Oct; 10(10):e640-e652. PubMed ID: 37494942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
    Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
    Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
    Tao X; Lu Y; Zhou Y; Zhang L; Chen Y
    Int J Infect Dis; 2020 Apr; 93():108-117. PubMed ID: 31988012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.
    Sarowar A; Coffin CS; Fung S; Wong A; Doucette K; Truong D; Conway B; Haylock-Jacobs S; Ramji A; Hansen BE; Janssen HLA; Cooper C
    J Acquir Immune Defic Syndr; 2022 Dec; 91(4):368-372. PubMed ID: 36288543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.
    Hermansson L; Yilmaz A; Price RW; Nilsson S; McCallister S; Makadzange T; Das M; Zetterberg H; Blennow K; Gisslen M
    PLoS One; 2019; 14(12):e0226276. PubMed ID: 31826005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
    De Clercq E
    Biochem Pharmacol; 2016 Nov; 119():1-7. PubMed ID: 27133890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
    Mills A; Arribas JR; Andrade-Villanueva J; DiPerri G; Van Lunzen J; Koenig E; Elion R; Cavassini M; Madruga JV; Brunetta J; Shamblaw D; DeJesus E; Orkin C; Wohl DA; Brar I; Stephens JL; Girard PM; Huhn G; Plummer A; Liu YP; Cheng AK; McCallister S;
    Lancet Infect Dis; 2016 Jan; 16(1):43-52. PubMed ID: 26538525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Agarwal K; Brunetto M; Seto WK; Lim YS; Fung S; Marcellin P; Ahn SH; Izumi N; Chuang WL; Bae H; Sharma M; Janssen HLA; Pan CQ; Çelen MK; Furusyo N; Shalimar D; Yoon KT; Trinh H; Flaherty JF; Gaggar A; Lau AH; Cathcart AL; Lin L; Bhardwaj N; Suri V; Mani Subramanian G; Gane EJ; Buti M; Chan HLY; ;
    J Hepatol; 2018 Apr; 68(4):672-681. PubMed ID: 29756595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.
    Mills A; Crofoot G; McDonald C; Shalit P; Flamm JA; Gathe J; Scribner A; Shamblaw D; Saag M; Cao H; Martin H; Das M; Thomas A; Liu HC; Yan M; Callebaut C; Custodio J; Cheng A; McCallister S
    J Acquir Immune Defic Syndr; 2015 Aug; 69(4):439-45. PubMed ID: 25867913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
    Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
    Antivir Ther; 2017; 22(5):443-446. PubMed ID: 28076335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group.
    Łomiak M; Stępnicki J; Mikuła T; Wiercińska-Drapało A
    Int J STD AIDS; 2021 May; 32(6):570-577. PubMed ID: 33612018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial.
    Post FA; Yazdanpanah Y; Schembri G; Lazzarin A; Reynes J; Maggiolo F; Yan M; Abram ME; Tran-Muchowski C; Cheng A; Rhee MS
    HIV Clin Trials; 2017 May; 18(3):135-140. PubMed ID: 28303753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.
    Gallant JE; Daar ES; Raffi F; Brinson C; Ruane P; DeJesus E; Johnson M; Clumeck N; Osiyemi O; Ward D; Morales-Ramirez J; Yan M; Abram ME; Plummer A; Cheng AK; Rhee MS
    Lancet HIV; 2016 Apr; 3(4):e158-65. PubMed ID: 27036991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.